FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2540177772> ?p ?o ?g. }

• W2540177772 endingPage "e0164240" @default.
• W2540177772 startingPage "e0164240" @default.
• W2540177772 abstract "To assess immunovirological response, safety and pharmacokinetic of NRTI-sparing regimen dual therapy of atazanavir (ATV) and raltegravir (RAL) in maintenance strategy.A retrospective analysis was conducted on a cohort of HIV-infected adults followed in French centers (Dat'AIDS cohort), comparing the proportions of virological and therapeutic failures between ATV + RAL and ATV/ritonavir + RAL dual therapy regimens.283 patients were assessed: 185 switched for ATV + RAL and 98 for ATV/ritonavir + RAL dual therapy. Virological failure rate at week 96 was 13.8% (95% CI, 9.8-17.8), without difference between the two groups (Log-rank Test, p = 0.87). The cumulative percentages of patients remaining free of therapeutic failure at week 24, 48 and 96 of dual therapy were 74.9% (95% CI, 69.9-80.0), 65.4% (95% CI, 59.8-70.9) and 53.4% (95% CI, 47.5-59.2), respectively. Four out of 39 confirmed virological failures developed RAL resistance. By multivariate analysis, virological failure was associated with high HIV-1 RNA zenith (p = 0.02), low CD4+ T-cell count at baseline (p<0.001) and short duration on antiretroviral therapy (p<0.001). Before week 96, dual therapy was discontinued in 44 patients (16%) because of various adverse events, with no difference between the two groups. Minimal plasma levels were targeted in 84% and 87% of patients for ATV and RAL, respectively, and both were significantly higher in ritonavir-boosted regimen.Emerging RAL-resistance and discontinuations for adverse events resulted in moderate efficacy rates of ATV and RAL dual therapy in heavily pretreated patients." @default.
• W2540177772 created "2016-11-04" @default.
• W2540177772 creator A5017068888 @default.
• W2540177772 creator A5019506568 @default.
• W2540177772 creator A5042793861 @default.
• W2540177772 creator A5057185222 @default.
• W2540177772 creator A5062566409 @default.
• W2540177772 creator A5068872303 @default.
• W2540177772 creator A5086090445 @default.
• W2540177772 creator A5089539215 @default.
• W2540177772 creator A5089604347 @default.
• W2540177772 date "2016-10-31" @default.
• W2540177772 modified "2023-10-16" @default.
• W2540177772 title "Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice" @default.
• W2540177772 cites W128919346 @default.
• W2540177772 cites W1497170016 @default.
• W2540177772 cites W1503584044 @default.
• W2540177772 cites W1958688023 @default.
• W2540177772 cites W1978347438 @default.
• W2540177772 cites W1978364917 @default.
• W2540177772 cites W1979035566 @default.
• W2540177772 cites W1983047835 @default.
• W2540177772 cites W1988633664 @default.
• W2540177772 cites W1989503541 @default.
• W2540177772 cites W1993559972 @default.
• W2540177772 cites W1998296720 @default.
• W2540177772 cites W2005925915 @default.
• W2540177772 cites W2007607803 @default.
• W2540177772 cites W2008250282 @default.
• W2540177772 cites W2011532461 @default.
• W2540177772 cites W2017480044 @default.
• W2540177772 cites W2029148240 @default.
• W2540177772 cites W2036539058 @default.
• W2540177772 cites W2061685109 @default.
• W2540177772 cites W2062642498 @default.
• W2540177772 cites W2070027063 @default.
• W2540177772 cites W2077432042 @default.
• W2540177772 cites W2113255660 @default.
• W2540177772 cites W2116304566 @default.
• W2540177772 cites W2116737560 @default.
• W2540177772 cites W2123055341 @default.
• W2540177772 cites W2136962231 @default.
• W2540177772 cites W2143357783 @default.
• W2540177772 cites W2144248766 @default.
• W2540177772 cites W2144713113 @default.
• W2540177772 cites W2154782100 @default.
• W2540177772 cites W2161167378 @default.
• W2540177772 cites W2161894299 @default.
• W2540177772 cites W2169264636 @default.
• W2540177772 cites W2169917092 @default.
• W2540177772 cites W2170726084 @default.
• W2540177772 cites W2179156013 @default.
• W2540177772 cites W2236174386 @default.
• W2540177772 cites W2312235623 @default.
• W2540177772 cites W2316844105 @default.
• W2540177772 cites W2409182456 @default.
• W2540177772 cites W39486528 @default.
• W2540177772 doi "https://doi.org/10.1371/journal.pone.0164240" @default.
• W2540177772 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5087881" @default.
• W2540177772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27798641" @default.
• W2540177772 hasPublicationYear "2016" @default.
• W2540177772 type Work @default.
• W2540177772 sameAs 2540177772 @default.
• W2540177772 citedByCount "5" @default.
• W2540177772 countsByYear W25401777722017 @default.
• W2540177772 countsByYear W25401777722018 @default.
• W2540177772 crossrefType "journal-article" @default.
• W2540177772 hasAuthorship W2540177772A5017068888 @default.
• W2540177772 hasAuthorship W2540177772A5019506568 @default.
• W2540177772 hasAuthorship W2540177772A5042793861 @default.
• W2540177772 hasAuthorship W2540177772A5057185222 @default.
• W2540177772 hasAuthorship W2540177772A5062566409 @default.
• W2540177772 hasAuthorship W2540177772A5068872303 @default.
• W2540177772 hasAuthorship W2540177772A5086090445 @default.
• W2540177772 hasAuthorship W2540177772A5089539215 @default.
• W2540177772 hasAuthorship W2540177772A5089604347 @default.
• W2540177772 hasBestOaLocation W25401777721 @default.
• W2540177772 hasConcept C112705442 @default.
• W2540177772 hasConcept C126322002 @default.
• W2540177772 hasConcept C142462285 @default.
• W2540177772 hasConcept C197934379 @default.
• W2540177772 hasConcept C203014093 @default.
• W2540177772 hasConcept C2778414717 @default.
• W2540177772 hasConcept C2779298103 @default.
• W2540177772 hasConcept C2780272996 @default.
• W2540177772 hasConcept C2780404665 @default.
• W2540177772 hasConcept C2781413609 @default.
• W2540177772 hasConcept C2993143319 @default.
• W2540177772 hasConcept C3013748606 @default.
• W2540177772 hasConcept C71924100 @default.
• W2540177772 hasConcept C72563966 @default.
• W2540177772 hasConcept C90924648 @default.
• W2540177772 hasConcept C98274493 @default.
• W2540177772 hasConceptScore W2540177772C112705442 @default.
• W2540177772 hasConceptScore W2540177772C126322002 @default.
• W2540177772 hasConceptScore W2540177772C142462285 @default.
• W2540177772 hasConceptScore W2540177772C197934379 @default.
• W2540177772 hasConceptScore W2540177772C203014093 @default.

• next